Renal involvement in systemic lupus erythematosus patients (SLE) is a severe disease manifestation characterized by various clinical and histopathological alterations. The revised ISN/RPN 2003 classification defines the subclasses of lupus nephritis (LN) according to their pathological glomerular patterns, which has a crucial impact on the prognosis and treatment options in LN patients. There are widely accepted therapeutic agents such as cyclophophamide, mycophenolate mofetil, azathioprine and corticosteroids available. Several trials tried to determine a gold standard for the induction and maintenance therapy in LN and the place of newer drugs, biologicals, is investigated. We review recently reported data on current treatment regimens in LN in particular in the context of the ISN/RPN 2003 classification. SS-A or SS-B have been found in kidney eluates from murine lupus models and from LN patients. 5-7 Moreover, it has been demonstrated that anti-DNA antibodies can also interact with glomerular constituents such as endothelial cells, type IV collagen, α-actinin-4 and heparan sulfate supporting the hypothesis of an immune complex mediated disease. 8;9 Together, this data provides further evidence that autoantibodies play a crucial role in the pathogenesis of LN. Therefore, B cells, as the source of antibodies, have been acknowledged as an important lymphocyte subset in the pathogenesis of SLE and LN in particular. Alterations of B cell numbers, activation status and function have been demonstrated. At first glance, B cells, being the source of autoantibodies, are regarded as the main actors in the immunological cascade Chapter 8 140 ending in organ injury. There is growing evidence that, besides autoantibody secretion, other functions of B cells such as antigen presenting capacity and cytokine production contribute to the development of SLE as well. Since the autoimmune response is autoantigen driven and T-cell dependent, also T cells are involved. For the interaction between B-and T-cells ligation of costimulatory molecules is necessary. 10 The increased expression of costimulatory molecules on B-and T-cells in SLE suggested novel therapeutic targets. 11;12 However, Tcells do more than initiation of B-cell activation. They can exert effector cell function themselves. The presence of T-cells in renal biopsies of LN patients and their presence in urine during active renal disease, support their migratory abilities and potential pathogenic role. 13;14
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease that is characterized by the production of autoantibodies to nuclear components. 1 The inflammatory response triggered by in situ formation and/or deposition of immune complexes is thought to be responsible for the various clinical manifestations such as vasculitis, nephritis and skin involvement. Especially, renal involvement, i.c. lupus nephritis (LN), remains a frequent and severe manifestation of SLE. Renal involvement in SLE is still one of the strongest predictors for morbidity and mortality. [2] [3] [4] Although over the last decades the therapeutic options for LN have increased leading to better results, the survival rate among patients with LN is still about 75 % after 15 years. 2 The underlying mechanisms in the pathogenesis of LN are still poorly understood. Numerous immunological abnormalities have been found to be associated with LN. However, which factors relate directly to renal inflammation remains unclear. Renal involvement in human SLE has often been considered as a classical immune complex induced glomerulonephritis (GN) due to deposition of preformed circulating immune complexes or binding of autoantibodies to glomerular antigens. Characteristic autoantibodies such as anti-dsDNA, but also antibodies with specifity for nucleosomes, Sm, histone, SLE patients. Therefore, a renal biopsy is mandatory. Thus, all patients suspected to have LN should undergo a renal biopsy, unless there are contraindications.
Treatment of LN requires an understanding of the immunopathology.
Therefore, we will briefly discuss the histopathological findings, which are characteristic for LN and are the basis for the ISN/RPS classification ( 
Histopathology
The (Table 1) . 18 The classification comprises six classes. The classification is based entirely on evaluation of glomerular alterations, although tubular, interstitial and vascular lesions are frequent findings in LN. Glomerular alterations are characterized by glomerular hypercellularity in the mesangial, endocapillary or extracapillary areas. Class I represents the mildest form of LN. Light microscopy reveals normal-appearing glomeruli, immunofluorescence microscopy however, shows mesangial immune deposits. Class II LN is defined as pure mesangial proliferation by light microscopy. Additionally, subendothelial or subepithelial deposits can be visible by immunofluorescence or electron microscopy. If there are on light microscopy endo-and/or extracapillary alterations visible, LN has to be classified as Class III or IV depending on the severity and distribution. In Class III, the focal lesions are typically segmental and involve less than 50 % of glomeruli. Class IV is defined as diffuse segmental and/or global endocapillary and/or extracapillary glomerulonephritis affecting more than or equal to 50 % of the glomeruli.
Furthermore is class IV subdivided into two categories to define whether the proliferative lesions are segmental (IV-S) or global (IV-G In order to evaluate LN more precisely, most investigators supplement the aforementioned ISN/RPS classification with a semiquantitative grading, developed at the National Institute of Health (NIH), to assess activity (potentially reversible lesions) and chronicity (irreversible lesions). 19 These histological features, listed in Table 2 , have to be graded on a scale of 0-3. Fibroid necrosis and cellular crescents are assigned double weight. The sum of all features evaluating the activity index yields a score of 0 to 24 and for the chronicity index a score of 0-12. Apart from the predictive value of these supplementary indices, the scoring of activity and chronicity provides important information about disease progression over time in case of sequential biopsies. Table 2 . The NIH scoring system for the activity and chronicity index is shown. Each item is graded on a scale of 0 -3. The more severe lesions (*) are multiplied by 2. The sum of all features yields a score for the activity index between 0-24 and for the chronicity index between 0-12.
Activity and Chronicity Index Activity
The understanding of the classification of LN has a major impact on the analysis of past and present studies evaluating treatment strategies. Due to the heterogeneous nature of LN, most studies enroll a selective cohort of patients based on the histopathological findings. Therefore, the therapeutic options will be discussed for the different classes of LN.
Immunosuppressive treatment of lupus nephritis

Class I lupus nephritis
In general there is no therapy necessary in patients with Class I LN in order to treat renal involvement ( Figure 1 ). Administration of immunosuppressive regimens is dependent on extra-renal manifestations and disease activity.
Patients should be monitored carefully and regularly to detect at an early stage transition to a more severe class of LN.
Class II lupus nephritis
In patients with mesangial proliferative Class II LN corticosteroids might be administrated to prevent disease progression and development of a class III or IV LN. Along with supportive treatment such as ACE-inhibitors in patients with proteinuria (>1.0 g/24 h) and/or active urinary sediment, prednisone can be given (0.5 -1 mg/kg/day, tapered to 0 over six months). Due to the lack of controlled studies, this recommendation is purely based on expert opinion. In addition, treatment with hydroxychloroquine can be considered. 21 Also in patients with Class II LN, regular monitoring of disease activity and renal parameters is mandatory.
Class III/IV lupus nephritis
Class III and IV LN have several pathogenic and histopathological similarities and patients with these types of LN share a poor long term renal survival due to deterioration of kidney function. Therefore, clinical trials usually comprise both groups. The first therapeutic goal is to reduce disease activity and to restore renal function or to prevent deterioration. Therefore, an aggressive treatment strategy (corticosteroids and cytotoxic drugs), so called induction therapy, is necessary for a period of time between 6 and 24 months. After successful induction therapy, long-term maintenance therapy is advocated to prevent renal relapses. 22 
Induction therapy
As induction therapy high dose intravenous cyclophosphamide (ivCy) in combination with high dose prednisone dominated for years treatment of LN, since long-term outcome, especially in terms of preservation of renal function, was superior over treatment with prednisone alone. 23;24 In these randomized p=0.04) and renal relapses (RR 4.9; CI: 1-6-15.0; p=0.06) occurred more frequently in the AZA/MP arm. Furthermore, infectious events, especially herpes zoster infections, were more often seen in the AZA/MP arm. 28 The clinical observation that the ivCy regimen is superior to AZA was supported by the histopathological assessment of renal biopsies obtained at study entry and after 2 years. 29 The renal specimens of the patient receiving AZA/MP showed a more pronounced progression of chronic lesions than in the ivCy arm (p=0.05).
Taken together, these studies show that the use of AZA/MP as induction therapy might be an option in selected patients, in particular women who do not accept the risk of infertility associated with ivCy.
In recent years mycophenolate mofetil (MMF) was evaluated as induction therapy. Several studies analyzed MMF in comparison to cyclophosphamide as induction therapy in SLE patients with proliferative LN.
One of the first was initiated by Chan et al. in 2000. 30 The use of MMF (2 g/day) versus oral cyclophosphamide (2.5 mg/kg/day) followed by AZA was tested in 
LN. To test this hypothesis a large study on behalf of the Aspreva Lupus
Management Study Group, the ALMS study, has been performed. 33 This study with monthly ivCy (750 mg/m 2 ). Steroids were given in both arms (start 3 times 500 mg methylprednisolon; thereafter 0.6-0.8 mg/kg with subsequent tapering). 34 At 6 and 9 months CR in the tacro/MMF arm was 50 and 65 % respectively, while for the ivCy arm this was 5 and 15 %. Extrapolation of these results is hampered by the short follow-up of this study and the fact that only Chinese patients were included.
In conclusion, the currently available data show that MMF and ivCy have at least equal efficacy for the induction treatment of proliferative LN, but ivCy is associated with more severe adverse effects, particularly infections and infertility. Although MMF has obviously a more favourable profile, a final judgement has to be postponed until long-term data regarding MMF treatment become available. MMF seems to be the preferable therapy especially in blacks and young female patients with pregnancy wishes. 35 However, MMF can not be used during pregnancy because of its teratogenic effects. Apart from these criteria, the therapy decision can be driven by several other factors such as patients' compliance, drug intolerance or earlier treatment regimens. The choice for induction therapy in an individual patient should take into account all these aspects.
Maintenance therapy
The 
Class VI lupus nephritis
Class VI LN is characterized by irreversible scarring of renal tissue, without inflammatory activity. Therefore, patients suffering from class VI LN do not benefit from immunosuppressive treatment regimens and, unavoidable, will reach end-stage renal disease (ESRD). In the context of ESRD renal replacement therapies should be discussed such as dialysis or transplantation, as recently reviewed.
47
Supportive therapy
Apart from the risk of progressive loss of renal function, various co-morbidities are associated with LN. Moreover, adverse effects due to therapeutic regimens contribute to an increased morbidity in LN patients. Therefore, the reduction of mortality and preservation of renal function remains an important aim. Initially, hydrochloroquine (HCQ) was mainly prescribed for patients with mild lupus manifestations (skin lesions; arthritis). However, a recent meta-analysis revealed that additional treatment with HCQ decreases disease activity; prevents flares; increases the probability of reaching a renal remission, improves survival, prevents irreversible organ damage and is safe and effective during pregnancy. 21 Therefore, it seems justified to prescribe HCQ (400 mg/day) as an adjunct treatment to all patients with LN, also in face of its low frequency of side-effects.
Additionally, the reduction of mortality can be approached by several supportive therapeutic measures, which have been recently reviewed by Masood et al. 48 Briefly, these therapies comprise medications controlling blood pressure, correcting dyslipidemia, preventing thomboembolic events and osteoporosis due to long-term therapy with corticosteroids.
It is well accepted that SLE patients have an increased cardio-vascular risk and therefore blood pressure control is crucial. 49;50 Blood pressure control can be ideally achieved by the use of angiotensin-converting enzyme (ACE)inhibitors or angiotensin receptor blockers. ACE-inhibitors have been shown to reduce proteinuria and to delay occurrence of renal involvement of SLEpatients. 51 Moreover, hyperlipidaemia should be addressed as well. Less evidence is available for the prophylactic long-term anticoagulation of LN patients although nephritis itself is a risk factor for thrombosis. 52 Agents directed against B-cells specifically targeting CD20
(rituximab/ocrelizumab) and CD22 (epratuzumab), have been investigated, since depletion or modulation of B-cells have been shown to be safe and effective in other autoimmune diseases than SLE. [54] [55] [56] The fact that pathogenic autoantibodies in SLE are produced by B-cells raised the idea that depletion of B-cells might be beneficial. Additionally, case reports and single centre experience in LN patients refractory to standard immunosuppression provided encouraging results that indeed B-cell depletion might be effective in the treatment of LN. 56 However, the results of the first RCT were disappointing. In the LUNAR study patients with LN (class III or IV) were randomized for rituximab (1000 mg at day 1, 15, 168 and 182) or placebo which was given on top of standard of care treatment, being MMF (1500 mg twice daily) and oral prednisone (60 mg initially, with subsequent tapering). 57 In both arms 72 patients were included. There were no differences in CR or partial remission between both groups (p = 0.55). The only significant difference in rituximab treated patients was a larger decrease in anti-dsDNA titers and a more pronounced increase in C3 levels. So, in patients with proliferative LN, addition of rituximab to induction therapy with MMF did not provide better (short-term) results.
The BELONG (NCT00626197) study enrolled SLE patients with biospsy proven class III and IV LN to evaluate whether the addition of the humanized anti-CD20 antibody (ocrelizumab) to standard immunosuppressive care did provide additional benefit. This study was stopped prematurely because of an The impact of B-and T-cell interaction via costimulation is well known.
CTLA4Ig is homologue to CD28 and binds to CD80/CD86 with high affinity.
Infusion of CTLA4Ig obviously results in downregulation of B cell activity by blocking the CD28-CD80/CD86 pathway. In human trials CTLA4Ig (abatacept) has been successfully evaluated in rheumatoid arthritis. 59 Results of controlled studies in patients with SLE are currently not available, but are ongoing. A phase-II multicenter trial (NCT00774852, ACCESS study) will evaluate the additional effect of abatacept to the ELNT regimen in LN patients. A benefical effect might be expected, as high levels of co-stimulatory molecules, especially CD80 and CD86 on B cells, were also found in human SLE. 11;60 In a murine LN model, synergistic effects of abatacept with ivCy have been demonstrated. 61 Furthermore, expression of CD134L has been shown to be up-regulated in proliferative LN, suggesting a role for the CD134-CD134L pathway in its pathogenesis. CD134 expression was correlated with disease activity and associated with renal involvement in human SLE. 12 ;62 A current study in BxBS mice demonstrated that blocking this interaction could be an effective alternative target to attenuate LN. 63 This could be a promising future therapeutic target in LN. An antagonist against CD154 (CD40L) has been examined as a possible therapeutic approach in human LN. But short-term administration of anti-CD154 was associated with increased thrombosis, despite initial encouraging data about serology and renal function. 64 Beside the elimination/modulation of B-cells, also biologicals targeting anti-dsDNA antibodies directly have been investigated. There is substantial evidence that anti-dsDNA antibodies are involved in the pathogenesis of LN.
Abetimus sodium (LJP-394) is a synthetic biological agent which is composed of four double stranded oligonucleotides linked to a non immunogenic polyethylene glycol platform. The ratio to use this construct was either as an antagonist for the B cell receptor for DNA or as a decoy-antigen for anti-dsDNA antibodies. Intravenous administration of abetimus results in a rapid reduction of circulating anti-dsDNA antibody titres. 65 This recommendation is based on good results of rituximab therapy reported in (large) case-series of patients with (refractory) LN. [70] [71] [72] The effect of rituximab in the LUNAR study might have gone unnoticed due to the relative mild to moderate lupus disease activity in the patients included. Furthermore, standard of care immunosuppressions is apparently sufficient in the majority of patients.
The beneficial effects of rituximab become clear in those patients who have failed on other immunosuppressives. Besides this study design, which reduced the power of the study to detect a favourable response to rituximab in LN, longterm data are necessary. 73 
Expert Commentary & Five-year view
In the last decade many studies provided useful information contributing to a better insight into the pathogenesis of SLE and to improvement of therapy.
Current treatments appear to be relatively safe and efficacious in a large proportion of SLE patients. However, LN remains a difficult entity among SLE manifestations and therefore the therapeutic regimens are more complex and more toxic. Long term follow-up data are mandatory to define successful responses to treatment and to detect of possible long term adverse effects.
Long-term data are available at least for the induction therapy with AZA/MP (Dutch Lupus Nephritis Trial) and low dose ivCy in proliferative LN (EURO-Lupus trial). Additionally, initial results of alternative induction therapies i.e. with MMF are promising (ALMS-study), but long-term data are essential and can be expected within the next years. On the basis of these studies the following conclusions can be drawn so far:
• for Caucasian patients low dose ivCY (6x500 mg, fortnightly) is an effective induction treatment
• MMF (2x 1.5 g/day) seems to be an alternative induction treatment, especially for black patients. However, one should realize that longterm data are lacking.
• Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in
